D'Incau Stéphanie, Atkinson Andrew, Leitner Lorenz, Kronenberg Andreas, Kessler Thomas M, Marschall Jonas
Infectious Diseases, Cantonal Hospital of Lucerne, Lucerne, Switzerland.
Department of Infectious Diseases, Inselspital, Bern University Hospital, Bern, Switzerland.
Antimicrob Steward Healthc Epidemiol. 2023 Mar 20;3(1):e55. doi: 10.1017/ash.2022.340. eCollection 2023.
To investigate clinically relevant microbiological characteristics of uropathogens and to compare patients with catheter-associated urinary tract infections (CAUTIs) to those with non-CAUTIs.
All urine cultures from the calendar year 2019 of the Swiss Centre for Antibiotic Resistance database were analyzed. Group differences in the proportions of bacterial species and antibiotic-resistant isolates from CAUTI and non-CAUTI samples were investigated.
Data from 27,158 urine cultures met the inclusion criteria. , , , and together represented 70% and 85% of pathogens identified in CAUTI and non-CAUTI samples, respectively. was significantly more often detected in CAUTI samples. The overall resistance rate for the empirically often-prescribed antibiotics ciprofloxacin (CIP), norfloxacin (NOR), and trimethoprim-sulfamethoxazole (TMP-SMX) was between 13% and 31%. Except for nitrofurantoin, from CAUTI samples were more often resistant ( ≤ .048) to all classes of antibiotics analyzed, including third-generation cephalosporines used as surrogate for extended-spectrum β-lactamase (ESBL). Significanty higher resistance proportions in CAUTI samples versus non-CAUTI samples were observed for CIP ( = .001) and NOR ( = .033) in , for NOR ( = .011) in , and for cefepime ( = .015), and piperacillin-tazobactam ( = .043) in
CAUTI pathogens were more often resistant to recommended empirical antibiotics than non-CAUTI pathogens. This finding emphasizes the need for urine sampling for culturing before initiating therapy for CAUTI and the importance of considering therapeutic alternatives.
研究尿路病原体的临床相关微生物学特征,并比较导管相关尿路感染(CAUTI)患者与非CAUTI患者。
分析了瑞士抗生素耐药性中心数据库2019年全年的所有尿培养结果。研究了CAUTI和非CAUTI样本中细菌种类和耐药菌株比例的组间差异。
27158份尿培养数据符合纳入标准。 、 、 和 分别占CAUTI和非CAUTI样本中鉴定出的病原体的70%和85%。 在CAUTI样本中检出率明显更高。经验性常用抗生素环丙沙星(CIP)、诺氟沙星(NOR)和甲氧苄啶-磺胺甲恶唑(TMP-SMX)的总体耐药率在13%至31%之间。除呋喃妥因外,CAUTI样本中的 对所有分析的抗生素类别(包括用作超广谱β-内酰胺酶(ESBL)替代物的第三代头孢菌素)耐药性更高( ≤.048)。在 中,CAUTI样本对CIP( =.001)和NOR( =.033)的耐药比例显著高于非CAUTI样本;在 中,对NOR( =.011)的耐药比例显著高于非CAUTI样本;在 中,对头孢吡肟( =.015)和哌拉西林-他唑巴坦( =.043)的耐药比例显著高于非CAUTI样本。
与非CAUTI病原体相比,CAUTI病原体对推荐的经验性抗生素耐药性更高。这一发现强调了在开始治疗CAUTI之前进行尿培养采样的必要性,以及考虑治疗替代方案的重要性。